Market research
ARAV Aravive Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 0.25
- Dividend yield
- Not available
- Beta
- 2.19
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03890D1081
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 0.25
- Dividend yield
- Not available
- Beta
- 2.19
About
About Aravive Inc
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ARAV discussion.
5 years, 4 months ago
Aravive, Inc is currently in a long term downtrend where the price is trading 9.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 16.8.
Aravive, Inc's total revenue rose by inf% to $6M since the same quarter in the previous year.
Its net income has increased by 6.5% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 158.5% to $4M since the same quarter in the previous year.
Based on the above factors, Aravive, Inc gets an overall score of 4/5.